期刊文献+

t-PA基因克隆及pcDNA3.1t-PA真核表达质粒的构建 被引量:2

Cloning t-PA gene and constructing pcDNA3.1 (+)/t-PA expression vector
下载PDF
导出
摘要 目的 利用基因工程技术克隆组织纤溶酶原激活物 (t PA)基因并构建一种无细胞毒性、不激活原癌基因的真核表达的pcDNA3.1t PA质粒载体。 方法 采用高效Trizol试剂快速从人肺组织中提取RNA ,RT PCR获得t PAcDNA ,扩增、纯化、回收t PA基因片段并将质粒 pcDNA3.1和t PA基因片段分别双酶切 ,前者纯化回收大片段 ,后者纯化回收 1 .9kb片段 ,再将回收的pcDNA3.1大片段与t PA基因片段 (1 .9kb)重组。对重组pcDNA3.1t PA质粒进行单酶切和双酶切鉴定 ,并测序。结果 成功地从胎儿肺组织中克隆了t PA基因 ,并构建了以pcDNA3.1为载体的真核表达质粒载体。结论 含t Objective To clone tissue type plasminogen activator (t PA) gene and to construct a new kind of recombinant vector containing human tissue type plasminogon activator (t PA) cNDA neither cytotoxiaty nor actovating prot oncogenes.Methods The RNA was extracted from human lung with efficient Trizol reagent. The t PA cDNA was obtained from it by reverse transcription polymerase chain reaction (RT PCR) and was amplified, purified and retrieved. To digest pcDNA3.1t PA plasmid and t PA gene with dual endonuclease, we retrieved a big fragment from pcDNA3.1 and a 1.9 kb fragment from t PA gene. Recombined the big fragment and 1.9 kb fragment. The recombination pcDNA3.1t PA plasmid and t PA gene was identified and sequenced by mono endonuclease and dual endonuclease.Results We succeeded in cloing t PA gene from fetal lung and constructed a sort of eukaryon expression plasmid vector with pcDNA3.1. t PA 6.9 kb fragment was found in the recombination pcDNA3.1 (+)/t PA after digesting with mono endonuclease. Digesting the 6.9 kb fragment with dual endonuclease, we obtained two fragments .One is 5.0 kb, another is 1.9 kb. It was identified by sequencing that the length of the 6.9 kb fragment was same as that human being's.Conclusion A new eukaryon expression plasmid with t PA gene has been constructed. It establishes the basics for gene treating local thrombosis after angioplasty.
出处 《重庆医学》 CAS CSCD 2004年第1期76-78,共3页 Chongqing medicine
基金 国家自然科学基金资助项目 (30 2 70 51 4 )
关键词 基因克隆 组织纤溶酶原激活物 真核表达质粒载体 gene cloning tissue type plasminogen activator eukaryon expression plasmid
  • 相关文献

参考文献2

二级参考文献10

  • 1Feldman LJ, Tahlil O, Steg G, et al. Perspectives of arterial gene therapy for the prevention of rest. enosis, Cardiovasc Res, 1996, 32: 194.
  • 2Mann MJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA,1995. 92: 4502.
  • 3Morishita R, Gibbons GH, Horiuchi M, et al. Agene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA,1995, 92: 5855.
  • 4Chang MW, Barr E, Lu MM, et el. Adenovirus-mediated over. expression of the cyclin/cyclin-depend-ent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995, 96: 2260.
  • 5Gerard RD, Collen D. Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis.Cardiovasc Res. 1997, 35: 451.
  • 6Isner JM, Walsh K, Rosenfield K, et al. Clinical protocol: arterial gene therapy for restenosis. Hum Gene Ther, 1996, 7: 989.
  • 7Zoldhelyi P, Mcnatt J, Xu XM, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenasc gene. Circulation, 1996, 93: 10.
  • 8Brieger D, Topol E. Local drug delivery systems and prevention of restenosis. Cardiovasc Res, 1997,35: 405.
  • 9Nabel EG: Gene therapy for cardiovascular disease.Circulation, 1995, 91: 541.
  • 10边杰芳.反义技术治疗自体移植静脉再狭窄的研究[J].外科理论与实践,1998,3(1):52-54. 被引量:2

共引文献2

同被引文献7

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部